In this podcast, experts Eileen O’Reilly, MD, and Brian Wolpin, MD, MPH, discuss current principles for molecular testing and emerging targeted therapy approaches for patients with metastatic pancreatic ductal adenocarcinoma. 

Upon successful completion of this activity, you should be better prepared to:

This activity is supported by an educational grant from Revolution Medicines.  

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

1.      Listen to this podcast in its entirety. 

2.      Go to gotoper.com/credit and enter code: 9235

3.      Answer the evaluation questions.

4.      Request credit using the drop-down menu.

You may immediately download your certificate.

Professor of Medicine

Winthrop Rockefeller Chair in Medical Oncology

Section Head, Hepatopancreaticobiliary & Neuroendocrine Cancers, Gastrointestinal Oncology Service

Associate Director, David M. Rubenstein Center for Pancreatic Cancer Research

Memorial Sloan Kettering Cancer Center

New York, NY

Disclosures: Consultant: AbbVie, Alligator Bioscience, AstraZeneca, Autem, Berry Genomics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Incyte, Ipsen, J-Pharma, Merck, Merus, Neogene, Novartis, Servier, Tango, Tempus, Vector, Yiviva; Institutional research support: Agenus, Arcus, AstraZeneca, BioNTech, Bristol Myers Squibb, Elicio, Genentech/Roche, Helsinn, Parker Institute, Pertzye, Puma, QED, Servier, Yiviva.

Professor of Medicine

Director, Gastrointestinal Cancer Center

Director, Hale Family Center for Pancreatic Cancer Research

Robert T. & Judith B. Hale Chair in Pancreatic Cancer

Harvard Medical School

Dana-Farber Cancer Institute

Boston, MA

Disclosures: Consulting/advisory board: Agenus, BeiGene, EcoR1 Capital, Harbinger Health, Ipsen, Mirati/Bristol Myers Squibb (BMS), Revolution Medicines, Tango Therapeutics, Third Rock Ventures; Funding (paid to institution): Agios, Amgen, AstraZeneca, Eli Lilly, Harbinger Health, Novartis, Revolution Medicines.

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on targeted therapy approaches for metastatic PDAC, go to https://www.gotoper.com/annual-oncology-meeting-25-pdac-activity

July 30, 2025

July 30, 2026 

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.